Share on StockTwits

Neuralstem (NYSE:CUR) Insider Karl Johe sold 6,000 shares of the stock on the open market in a transaction dated Friday, August 1st. The stock was sold at an average price of $2.78, for a total value of $16,680.00. Following the completion of the transaction, the insider now directly owns 484,247 shares in the company, valued at approximately $1,346,207. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Zacks reiterated an “outperform” rating on shares of Neuralstem in a research note on Wednesday, June 25th. They now have a $7.00 price target on the stock. Separately, analysts at Aegis raised their price target on shares of Neuralstem from $6.00 to $7.00 in a research note on Wednesday, June 25th. They now have a “buy” rating on the stock. Finally, analysts at Aegis raised their price target on shares of Neuralstem to $6.00 in a research note on Tuesday, May 27th.

Neuralstem (NYSE:CUR) traded up 4.98% during mid-day trading on Monday, hitting $3.16. 684,558 shares of the company’s stock traded hands. Neuralstem has a one year low of $1.43 and a one year high of $4.81. The stock’s 50-day moving average is $3.6 and its 200-day moving average is $3.73. The company’s market cap is $274.2 million.

Neuralstem (NYSE:CUR) last announced its earnings results on Monday, May 12th. The company reported ($0.07) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.06) by $0.01. The company had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.35 million. Analysts expect that Neuralstem will post $-0.25 EPS for the current fiscal year.

Neuralstem, Inc is a development-stage company focused on the development and commercialization of treatments for central nervous system disease based on transplanting human neural stems cells and the use of small molecule drugs.

Receive News & Ratings for Neuralstem Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.